As living organisms, bacteria are encoded by DNA, and DNA occasionally mutates. Sometimes genetic mutations render a bacterium immune to an antibiotic’s chemical tactics. The few cells that might escape antibiotic pressure then have a sudden advantage: with their counterparts wiped out, resources abound, and the remaining antibiotic-resistant bacteria proliferate. It’s a problem not only for the host—you or me when we are treated with an antibiotic and develop a resistant strain—but also for anyone with whom we happen to share our resistant bacteria, say, on a door handle or keyboard. In fact, most resistant bacteria develop not in people but in livestock fed antibiotics to promote growth; these resistant bacteria infect people through contaminated animal products. This is how even antibiotic “naive” people come to be infected with resistant strains of bacteria.

I see this all the time as a family doctor. A woman has a urinary tract infection. I tell her that her bacteria are resistant to this or that antibiotic, and she says, “But I’ve never taken any of those.” Welcome to the global human soup.

  • girlfreddyOP
    link
    fedilink
    arrow-up
    10
    arrow-down
    1
    ·
    3 months ago

    The article discusses the ‘newest’ form of treatment …

    BACTERIOPHAGES, or phages for short, are viruses that attack bacteria and kill them; the two organisms have been involved in an evolutionary cat-and-mouse game for millions of years. Phages are ever present in the environment, from sea water to barnyard waste—anywhere bacteria are found in high numbers.

    • HopeOfTheGunblade@kbin.social
      link
      fedilink
      arrow-up
      5
      arrow-down
      1
      ·
      3 months ago

      Phage therapy has issues. It’s generally hyperspecific, with every strain of bacteria having its own phage, most of which we don’t have, and which they can become resistant to.

      • girlfreddyOP
        link
        fedilink
        arrow-up
        6
        ·
        3 months ago

        The article deals with that.

        Greg German, a medical microbiologist at Unity Health Toronto, has collaborated at times with Nancy Tawil, a biomedical engineer with experience in phage production for the US-based company Precisio Biotix Therapeutics and as CEO of Qeen BioTherapeutics based in Gatineau, Quebec. For years, her production teams have been collecting libraries of phages from all over the world that infect and kill common human pathogens, such as Staphylococcus, Pseudomonas, Klebsiella, and Acinetobacter, all of which can cause life-threatening lung, brain, and blood infections. To date, most of Tawil’s research has been done on patients in the US. Qeen receives a sample of infected tissue, isolates the bacteria, screens its library for an effective phage—usually a cocktail of up to five phages—then ferments, multiplies, and purifies the phages, and delivers the mixture to the clinical team. That process takes between a week and two weeks. The price tag? About $45,000. According to Tawil, that’s the cost of making 200 litres of phage solution, whereas a patient might need only fifty millilitres for their treatment. Sometimes a phage found for one person can also work on another, reducing the cost of treatment per person.